In CML, gliptins inhibit aberrantly expressed membrane-bound DPPIV, thereby restoring the disrupted SDF1 gradient resulting in normalization of the interaction within the hematopoietic niche. Here, DPP4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.